Cite
HARVARD Citation
Modlin, I. et al. (2021). Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of surgery. 274 (3), p. . [Online].